undamentalytics Newsletter
Sign in

Myriad Genetics Inc (MYGN) stock

Add to watchlist

Add holding +

NASDAQ: MYGN Nasdaq Health Care Equipment Next results ~November 4, 2026

C Fundamentals grade

Myriad Genetics Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$6.7

Valuation models combined (3)

Base case. Range ~$5.0–$11. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Myriad Genetics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 1 selling5 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds116 adding, 101 cuttingOf 49 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Myriad Genetics files

Where Myriad Genetics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $807m, down 3.2% on a year earlier, a steeper fall than the 0.3% decline a quarter earlier. That puts it 53 of 58 for growth among the health care equipment companies we cover. Free-cash-flow margin rose to -4.2% from -8.8% a year earlier. Operating margin widened to -12.2% from -50.1%. The diluted share count is up 2.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $8.34 a share, against a share price of $6.64.

Source: 10-Q filed July 31, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Myriad Genetics Inc's trailing-twelve-month revenue fell 3.2% year on year, with a free-cash-flow margin of -4.2%. Where it lags: revenue growth of -3.2% ranks 106 of 129 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 54.0% while net income grew 71.5%: a 18pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 37.9 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 3.2% over the last 12 months.
  • Loss-making. Operating margin is -12.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -4.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 87% and a beta of 1.2 against the S&P 500.
  • Growth easing. The growth rate is 2.9 points lower than a quarter earlier.

Latest results: FY2026 Q2

Filed July 31, 2026
Earnings per share
-$0.25 against an average estimate of -$0.06: missed by 332.7%
Revenue
$191m, down 10.5% on a year earlier
Share reaction
-43.3% in the first session after the results on July 30, 2026, against +2.4% for the S&P 500
Guidance given
revenue $770m to $790m (2026 Guidance); adjusted Gross Margin % 66% to 67% (2026 Guidance)
Next report
November 4, 2026; average EPS estimate -$0.20

Myriad Genetics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.5%
  • 1 week-5.6%
  • 1 month+30.7%
  • This year-4.9%
  • 1 year-27.4%
  • 5 years-80.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$807M
Operating margin
-12.2%
Net margin
-14.0%
EPS (TTM, diluted)
$-1.20

Growth

Revenue growth
−3.2%
Change in growth rate
−2.9 pts
Share count change
+2.5%

Cash

Free cash flow (TTM)
-$33.9M
FCF margin
-4.2%
Stock pay % of revenue
3.6%

Earnings

Last results
July 30, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Leadership
  4. Results
  5. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Myriad Genetics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Myriad Genetics Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.01 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.0 ~$3.0–$6.3 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$11 ~$12–$40 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.2 ~$8.2–$11 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.7 ~$5.0–$11 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Myriad Genetics Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$30.60$25.84$37.37$27.78$11.34$27.60$14.51$19.14$13.71$6.15$5.85
Market value$2.2bn$1.8bn$2.7bn$2.1bn$843m$2.2bn$1.2bn$1.6bn$1.2bn$569m$548m
+ Net debt (− = net cash)$0$0$0$0$0−$257m−$57m−$94m−$62m−$25m$10m
Enterprise value$2.2bn$1.8bn$2.7bn$2.1bn$843m$1.9bn$1.1bn$1.5bn$1.2bn$545m$558m
Multiples
Price / sales 3.0x2.3x3.6x2.5x1.3x3.1x1.7x2.1x1.5x0.7x0.7x
Price / earnings 19.2x102.2x20.2xn/m———————
Price / free cash flow 13.9x17.8x25.0x28.1x16.7xn/m———n/m71.2x
EV / EBITDA 12.5x19.3x15.3x26.2x———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

26 /100

Weak moat

How hard Myriad Genetics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -10.5% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -21.4%; its worst year was -50.1%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 4 of 10 years, at a median -4.0% of revenue.

  • Discipline 7 / 20

    The diluted share count rose 23.7% over five years; stock-based pay has been a median 4.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $191m and EPS of −$0.20 (range −$0.27 to −$0.15) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.74 −1332% $778m −6%
Next −$0.59 +20% $820m +6%

Next year's EPS estimate has moved −489.6% in 90 days, across 9 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1646.8% on 90 days ago. In the last 30 days, 0 analysts raised Myriad Genetics Inc's forecast and 0 cut it.

Consensus EPS forecast Myriad Genetics Inc, last 90 days
−$1.00 −$0.50 $0.00 $0.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.05 Current fiscal year, 60 days ago: −$0.76 Current fiscal year, 30 days ago: −$0.75 Current fiscal year, 7 days ago: −$0.74 Current fiscal year, Now: −$0.74 −$0.74 Next fiscal year, 90 days ago: $0.15 Next fiscal year, 60 days ago: −$0.57 Next fiscal year, 30 days ago: −$0.57 Next fiscal year, 7 days ago: −$0.59 Next fiscal year, Now: −$0.59 −$0.59

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.05$0.15
60 days ago −$0.76−$0.57
30 days ago −$0.75−$0.57
7 days ago −$0.74−$0.59
Now −$0.74−$0.59

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.06 −$0.25 −332.7%
Mar 2026 −$0.07 −$0.09 −34.7%
Dec 2025 −$0.02 $0.04 +348.3%
Sept 2025 −$0.01 $0.00 +100.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 30, 2026
  • Revenue 2026 Guidance $770m to $790m Lowered
    “Revenue $770 - $790 Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends.” source
  • Adjusted Gross Margin % 2026 Guidance 66% to 67% Non-GAAP
    “Adjusted Gross Margin %** 66% - 67% Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

9 analysts, Oct 2026
Buy111%
Hold667%
Sell222%

Monthly trend

  1. Oct 202616119
  2. Sep 202615129
  3. Aug 2026115119
  4. Jul 2026114118

Counts of recommendations published by analysts covering Myriad Genetics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.9%
of tradable shares
Days to cover
4.59
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
97%
of shares
Held by insiders
4.0%
of shares
Employees
2,700
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −27.2%

$8.04 on October 31, 2025 to $5.85

ThenNowEffect
Revenue (last 12 months) $833m $807m −3.2%
P/S multiple 0.9x 0.7x −23.0%
Share count 91m 94m −2.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −65.6%

$17.02 on November 3, 2023 to $5.85

ThenNowEffect
Revenue (last 12 months) $699m $807m +15.4%
P/S multiple 2.0x 0.7x −65.6%
Share count 81m 94m −13.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MYGN+40%−47%+32%−28%−55%−5%
Industry peers (median)−9%−37%−9%−19%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MYGN50%25%50%50%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MYGN−34%−48%−42%−54%−74%−57%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from September 4, 2018 to July 31, 2026. Getting back needed a 1660% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.86 – $8.18
From 52-week high
−28.5%
vs 50-day average
+37.1%
vs 200-day average
+27.0%
Volatility (1 year)
87%
Beta vs S&P 500
1.22

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±18.1%
After a week
3 up, 9 down
typical move ±22.0%
After a month
4 up, 8 down
typical move ±23.6%
Results releasedNext dayS&P 500 next day5 days21 days
July 30, 2026 −43.3% +2.4% −36.9% −37.3%
May 5, 2026 −16.8% +2.2% −17.6% −5.1%
February 23, 2026 +3.3% −0.3% +16.8% +7.5%
January 12, 2026 −5.8% 0.0% −13.7% −26.3%
November 3, 2025 −19.7% −1.0% −19.4% −8.8%
August 5, 2025 +42.5% +0.3% +51.5% +70.6%
May 6, 2025 −44.5% −0.4% −46.6% −36.1%
February 24, 2025 −17.2% −1.0% −26.7% −31.4%
January 15, 2025 −8.5% +1.6% −6.7% +6.4%
November 7, 2024 −0.9% +1.2% −10.8% −15.3%
October 9, 2024 −11.1% +0.5% −7.9% −31.9%
August 6, 2024 +3.1% +0.2% +9.1% +7.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Myriad Genetics Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Myriad Genetics Inc
$700M $750M $800M $850M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $734.4M Revenue (TTM), FY23 Q4: $753.2M Revenue (TTM), FY24 Q1: $774.2M Revenue (TTM), FY24 Q2: $802.2M Revenue (TTM), FY24 Q3: $823.6M Revenue (TTM), FY24 Q4: $837.6M Revenue (TTM), FY25 Q1: $831.3M Revenue (TTM), FY25 Q2: $832.9M Revenue (TTM), FY25 Q3: $825.3M Revenue (TTM), FY25 Q4: $824.5M Revenue (TTM), FY26 Q1: $829M Revenue (TTM), FY26 Q2: $806.6M $806.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $734.4M
FY23 Q4 $753.2M
FY24 Q1 $774.2M
FY24 Q2 $802.2M
FY24 Q3 $823.6M
FY24 Q4 $837.6M
FY25 Q1 $831.3M
FY25 Q2 $832.9M
FY25 Q3 $825.3M
FY25 Q4 $824.5M
FY26 Q1 $829M
FY26 Q2 $806.6M
Revenue growth, TTM YoY Myriad Genetics Inc
-5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 11.0% Revenue growth, TTM YoY, FY23 Q4: 11.0% Revenue growth, TTM YoY, FY24 Q1: 11.4% Revenue growth, TTM YoY, FY24 Q2: 14.8% Revenue growth, TTM YoY, FY24 Q3: 12.1% Revenue growth, TTM YoY, FY24 Q4: 11.2% Revenue growth, TTM YoY, FY25 Q1: 7.4% Revenue growth, TTM YoY, FY25 Q2: 3.8% Revenue growth, TTM YoY, FY25 Q3: 0.2% Revenue growth, TTM YoY, FY25 Q4: -1.6% Revenue growth, TTM YoY, FY26 Q1: -0.3% Revenue growth, TTM YoY, FY26 Q2: -3.2% -3.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 11.0%
FY23 Q4 11.0%
FY24 Q1 11.4%
FY24 Q2 14.8%
FY24 Q3 12.1%
FY24 Q4 11.2%
FY25 Q1 7.4%
FY25 Q2 3.8%
FY25 Q3 0.2%
FY25 Q4 -1.6%
FY26 Q1 -0.3%
FY26 Q2 -3.2%
Operating margin (TTM) Myriad Genetics Inc
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -37.9% Operating margin (TTM), FY23 Q4: -34.2% Operating margin (TTM), FY24 Q1: -30.1% Operating margin (TTM), FY24 Q2: -19.4% Operating margin (TTM), FY24 Q3: -14.1% Operating margin (TTM), FY24 Q4: -14.7% Operating margin (TTM), FY25 Q1: -15.0% Operating margin (TTM), FY25 Q2: -50.1% Operating margin (TTM), FY25 Q3: -51.0% Operating margin (TTM), FY25 Q4: -47.0% Operating margin (TTM), FY26 Q1: -46.9% Operating margin (TTM), FY26 Q2: -12.2% -12.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -37.9%
FY23 Q4 -34.2%
FY24 Q1 -30.1%
FY24 Q2 -19.4%
FY24 Q3 -14.1%
FY24 Q4 -14.7%
FY25 Q1 -15.0%
FY25 Q2 -50.1%
FY25 Q3 -51.0%
FY25 Q4 -47.0%
FY26 Q1 -46.9%
FY26 Q2 -12.2%
FCF margin (TTM) Myriad Genetics Inc
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -14.9% FCF margin (TTM), FY23 Q4: -21.5% FCF margin (TTM), FY24 Q1: -18.8% FCF margin (TTM), FY24 Q2: -18.4% FCF margin (TTM), FY24 Q3: -14.8% FCF margin (TTM), FY24 Q4: -7.1% FCF margin (TTM), FY25 Q1: -6.8% FCF margin (TTM), FY25 Q2: -8.8% FCF margin (TTM), FY25 Q3: -6.5% FCF margin (TTM), FY25 Q4: -5.7% FCF margin (TTM), FY26 Q1: -5.1% FCF margin (TTM), FY26 Q2: -4.2% -4.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -14.9%
FY23 Q4 -21.5%
FY24 Q1 -18.8%
FY24 Q2 -18.4%
FY24 Q3 -14.8%
FY24 Q4 -7.1%
FY25 Q1 -6.8%
FY25 Q2 -8.8%
FY25 Q3 -6.5%
FY25 Q4 -5.7%
FY26 Q1 -5.1%
FY26 Q2 -4.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-KT, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Jun 2009 2010 Jun 2010 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 327 363 402 496 613 778 723 754 771 744 851 639 691 678 753 838 825 807
Gross profit 283 318 356 445 549 682 590 621 626 — — — — 476 517 585 577 555
EBITDA 136 142 165 189 237 288 159 180 92 176 81 −160 −128 −88 −196 −62 −334 −64
Operating income 126 135 158 180 228 274 134 153 44 122 8 −232 −191 −141 −257 −124 −387 −99
Net income 85 152 101 112 147 176 80 117 17 133 5 −200 −27 −112 −263 −127 −366 −113
Diluted EPS $0.86 $1.54 $1.10 $1.30 $1.77 $2.25 $1.07 $1.60 $0.25 $1.85 $0.06 −$2.69 −$0.35 −$1.39 −$3.18 −$1.41 −$3.95 −$1.20
Growth (year on year)
Revenue — +11.1% +10.9% +23.4% +23.6% +26.9% −7.1% +4.2% +2.3% −3.6% +14.4% −25.0% +8.1% −1.8% +11.0% +11.2% −1.6% −3.2%
EBITDA — +4.6% +16.1% +14.8% +25.1% +21.7% −45.0% +13.6% −48.8% +91.0% −54.3% −298.1% — — — — — —
Operating income — +6.8% +16.8% +14.3% +26.4% +20.4% −51.3% +14.8% −71.3% +177.0% −93.8% — — — — — — —
Net income — +80.0% −33.9% +11.4% +31.3% +19.7% −54.7% +46.9% −85.2% +666.1% −96.5% — — — — — — —
Diluted EPS — +79.1% −28.6% +18.2% +36.2% +27.1% −52.4% +49.5% −84.4% +640.0% −96.8% — — — — — — —
Margins
Gross margin 86.7% 87.8% 88.6% 89.6% 89.5% 87.7% 81.6% 82.4% 81.2% — — — — 70.2% 68.6% 69.9% 69.9% 68.8%
EBITDA margin 41.6% 39.2% 41.0% 38.2% 38.6% 37.0% 21.9% 23.9% 12.0% 23.7% 9.5% −25.0% −18.5% −13.0% −26.0% −7.4% −40.4% −7.9%
Operating margin 38.7% 37.2% 39.2% 36.4% 37.2% 35.3% 18.5% 20.4% 5.7% 16.4% 0.9% −36.3% −27.6% −20.7% −34.2% −14.7% −47.0% −12.2%
Net margin 25.9% 42.0% 25.0% 22.6% 24.0% 22.6% 11.0% 15.5% 2.3% 17.9% 0.5% −31.2% −3.9% −16.5% −35.0% −15.2% −44.4% −14.0%
Free-cash-flow margin 23.4% 40.6% 31.6% 26.7% 26.5% 22.6% 16.1% 21.4% 13.0% 14.5% 8.8% 7.9% 0.1% −22.3% −14.7% −1.0% 0.2% 1.0%
Cash flow
Cash from operations 84 155 131 142 174 190 141 166 106 116 84 61 19 −106 −111 −9 2 8
Capital spending 8 8 4 9 11 14 24 5 6 8 9 10 18 45 0 0 0 0
Free cash flow 77 147 127 132 162 176 117 161 100 108 75 51 1 −152 −111 −9 2 8
Stock-based pay 26 23 25 26 27 27 46 32 30 27 34 25 36 38 41 50 35 29
Free cash flow after stock pay 51 124 102 106 136 149 71 130 70 80 42 25 −36 −190 −152 −59 −33 −21
Balance sheet
Cash — — — — — — — — — — — — 257 57 132 102 150 115
Total debt 0 0 0 0 0 0 0 0 100 10 235 227 0 0 39 41 125 125
Net debt (negative = net cash) — — — — — — — — — — — — −257 −57 −94 −62 −25 10
Diluted shares 99m 99m 92m 86m 83m 78m 75m 73m 69m 72m 76m 74m 78m 81m 83m 91m 93m 94m
Returned to shareholders
Buybacks — 71 200 128 146 288 211 163 32 0 50 0 0 — — — — —
Total returned — 71 200 128 146 288 211 163 32 0 50 0 0 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $639m
Short-term assets $289mLonger-term assets $350m
What it owes, and who funded it · $639m
Short-term liabilities $131mLonger-term liabilities $204mShareholders' equity $304m
  • Short-term assets cover short-term liabilities $289m of assets due within a year against $131m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $289m short-term assets against $204m of longer-dated liabilities.
  • More cash than debt $115m of cash against $121m of debt.
  • Debt below 40% of shareholders' equity Debt is 40% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 40% over five years.
  • A year's operating cash flow covers at least 20% of debt $8m of operating cash flow against $121m of debt.
  • Operating profit covers interest at least five times over Operating income of −$99m against $16m of interest.

From Myriad Genetics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.5%
year over year
R&D spending
13.1%
of revenue
Days sales outstanding
50 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated MYGN IRTC OFIX ATEC VREX INSP Median
Revenue, last 12 months $807m $825m $833m $840m $865m $881m $99m
Revenue growth, last 12 months −3.2% 25.6% 3.0% 15.3% 5.3% −0.2% 9.2%
Revenue growth, 3-year average 4.9% 22.2% 11.7% 23.1% −1.2% 15.6% 13.5%
Revenue growth, latest quarter −10.5% 20.1% 3.8% 12.6% 3.7% −7.9% 10.2%
Gross margin 68.8% 71.5% 71.3% 71.3% 34.3% 86.2% 61.2%
Operating margin −12.2% −3.0% −4.7% −3.6% 8.3% 1.8% −8.5%
Operating margin, 3-year average −27.2% −14.3% −9.7% −14.8% 3.1% 2.6% −17.9%
Net margin −14.0% −1.7% −7.4% −10.3% 2.6% 11.4% −12.0%
Cash from operations / revenue 1.0% 10.4% 2.0% 7.3% 1.3% 15.3% −1.9%
Free-cash-flow margin −4.2% 4.7% −3.3% −1.2% −2.3% 11.1% −3.9%
Free-cash-flow margin, 3-year average −10.5% −3.0% −4.2% −12.1% 2.4% 9.1% −7.0%
Stock pay / revenue 3.6% 10.1% 3.4% 9.0% 1.7% 13.3% 6.1%
Change in share count 2.5% 2.9% 3.6% 4.6% −8.8% −3.9% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -3.2% 9.1% 106 of 129
Change in growth rate Growth -2.9pp -0.6pp 92 of 129
Gross margin Profitability 68.8% 61.9% 43 of 123
Operating margin Profitability -12.2% -8.3% 72 of 132
Net margin Profitability -14.0% -12.0% 70 of 133
Free-cash-flow margin Cash generation -4.2% -3.4% 67 of 128
Stock pay as % of revenue Cash generation 3.6% 6.1% 47 of 123
Long-term debt as % of assets Balance sheet 18.9% 24.2% 36 of 87
Change in share count Balance sheet 2.5% 3.3% 51 of 115
Days sales outstanding Balance sheet 50 days 57 days 39 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Hereditary Cancer $372M 45.2% ▲ 2.2%
Prenatal $186M 22.6% ▲ 5.2%
Mental Health $144M 17.5% ▼ 15.3%
Tumor Profiling $122M 14.8% ▼ 3.3%
Geography
Region Revenue Share YoY
United States $768M 93.1% ▼ 0.2%
Outside the US $56.5M 6.9% ▼ 17.0%

From Myriad Genetics Inc's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$514M
Institutions reporting
195
Shares held vs prior quarter
▲ 2.2%
Positions opened / closed
41 / 43

Top buyers and sellers, Q2 2026: 116 institutions bought and 101 sold ; the biggest buyer was Vestal Point Capital, LP (+4.1M shares) and the biggest seller Glenview Capital Management, LLC (−5.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $62.2M 10.9M 12.1% ▲ 22.5%
Millennium Management LLC $37.8M 6.6M 7.4% ▼ 0.7%
Vestal Point Capital, LP $32.7M 5.7M 6.4% ▲ 248.0%
State Street Corp $28.5M 5.0M 5.5% ▲ 12.7%
D. E. Shaw & Co., Inc. $26.2M 4.6M 5.1% ▲ 1.8%
Vanguard Capital Management LLC $23.3M 4.1M 4.5% ▲ 4.0%
Acadian Asset Management LLC $17.8M 3.1M 3.5% ▲ 35.4%
Vanguard Portfolio Management LLC $17.6M 3.1M 3.4% ▲ 19.3%
AQR Capital Management LLC $15.8M 2.8M 3.1% ▲ 44.7%
Morgan Stanley $14.2M 2.5M 2.8% ▼ 21.7%
Geode Capital Management, LLC $13.8M 2.4M 2.7% ▲ 4.2%
Assenagon Asset Management S.A. $11.8M 2.1M 2.3% ▲ 42.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Myriad Genetics Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $722,223 5 trades by 3 insiders, last 12 months Insider sales History → $66,900 1 trade by 1 insider · 100% under pre-set plans
Net ▲ $655,323 net buying
Insider Date Trade Shares Price Value
Kumar Rashmi Director June 8, 2026 Sell pre-set plan 15,000 $4.46 $66,900
Bisaro Paul Director May 14, 2026 Buy 7,500 $3.69 $27,675
Raha Samraat S. President and CEO March 9, 2026 Buy 40,000 $5.00 $200,000
Phanstiel S. Louise Director February 27, 2026 Buy 48,000 $4.66 $223,680
Phanstiel S. Louise Director February 26, 2026 Buy 50,407 $4.80 $241,954
Phanstiel S. Louise Director February 25, 2026 Buy 6,100 $4.74 $28,914

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 9, 2026 estimated from the company's past filing pattern, not announced

  • July 30, 2026
  • May 5, 2026
  • February 23, 2026
  • January 12, 2026
  • November 3, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Myriad Genetics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Myriad Genetics Inc in brief

What does Myriad Genetics Inc do?
Myriad Genetics Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Myriad Genetics Inc's stock ticker?
Myriad Genetics Inc trades under the ticker MYGN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Myriad Genetics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Myriad Genetics Inc reported revenue of $807M, 3.2% lower than a year earlier, according to its SEC filings.
What is Myriad Genetics Inc's free cash flow?
Myriad Genetics Inc's free-cash-flow margin is -4.2% of revenue over the trailing twelve months, ranking 67 of the 128 health care equipment companies we cover.
Who are Myriad Genetics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Millennium Management LLC and Vestal Point Capital, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Myriad Genetics Inc's market cap?
On November 2, 2026, Myriad Genetics Inc's market capitalisation was about $548M and net debt of $9.8M. Market figures come from third-party market data and may be delayed.
How much debt does Myriad Genetics Inc have?
Myriad Genetics Inc's debt-to-equity ratio is 39.7%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Myriad Genetics Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Myriad Genetics Inc are Irhythm Holdings, Inc., Orthofix Medical Inc., Alphatec Holdings, Inc., Varex Imaging Corp and Inspire Medical Systems, Inc. The side-by-side comparison below sets their revenue, margins and growth against Myriad Genetics Inc's.
Are insiders buying or selling Myriad Genetics Inc stock?
Over the last 12 months, Myriad Genetics Inc's directors and officers reported 5 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Myriad Genetics Inc's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Myriad Genetics Inc announces its own schedule.